Provider review
Joi + Blokes Review: A Peptide Seller That Quantifies Results It Cannot Cite
Most peptide marketing hedges. Joi + Blokes quantifies. Its sermorelin FAQ says that by month six "studies suggest potential 5-10% body fat reduction (without diet or exercise), a 10% increase in lean muscle mass" — specific, attributed and falsifiable, which is useful, because it can be checked. It does not survive the check: the newest randomized trial in that literature is from 2005.
Joi + Blokes runs the best front end and the worst claims of the three providers reviewed here. The lab-first intake is genuine, the consultation is genuine, and the pricing is displayed more honestly than most of the market manages. Then the product pages attach numbers to peptides that no trial has produced — 5-10% body fat, 10% lean muscle, at six months, without diet or exercise, from a molecule whose newest randomized trial is twenty-one years old. A company that sells you a 110-biomarker panel and will not tell you the potency tolerance of the vial it ships has its measurement priorities the wrong way round. If you are buying the approved GLP-1s, the description is accurate. If you are buying the peptides, you are buying a specific promise with nothing behind it.
Worth trusting if
- You want both prices in front of you before you commit, because every product page shows the subscription rate and the one-time rate with the monthly equivalent worked out.
- You want blood work behind the prescription, because the storefront leads with 56-, 71- and 110-biomarker panels and flags rapamycin and low-dose naltrexone as lab-required.
- You want the approved GLP-1s described honestly, because the insurance FAQ separates them from the compounded line instead of blurring the two.
Be skeptical if
- You want the price you clicked on to be the price you pay, because the category listing and the sermorelin product page have disagreed on the monthly figure since at least August 7 and still did on August 25.
- You want a clinician to see you before you pay, because nothing in this checkout asks a single health question ahead of the card screen.
- You want the potency tolerance of the vial you are sent, because a company selling 110-biomarker panels publishes no testing standard, no certificate of analysis and no pharmacy name for the compounded products.
Approved + compounded
Phase 3 trials
Not named
June 2026
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens joiandblokes.com. A link is not a recommendation to take anything.
Provenance
What Joi + Blokes actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
The finished product holds an FDA approval and carries an NDC. Approval covers the specific product, dose form and indication on the label — not the molecule in general.
- Zepbound® (tirzepatide injection) — Priced separately from the compounded line; Joi + Blokes does not bill insurance directly but assists with prior authorizations for the branded products.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded GLP-1 / GLP-1+GIP — The compounded GLP-1 line is priced on a page that returned a Cloudflare 403 to every request on August 7, 2026, so no figure for it is published in this review. The quotations above come from the FDA letter, which reproduces them.
- Sermorelin Peptide Therapy (injections or troches) — $559 for a 12-week supply on subscription, which the page itself renders as $186.33 a month, or $699 one-time, rendered as $233 a month. The site navigation separately advertises "Sermorelin Peptide Therapy … $199/mo," which is neither figure.
- VIP Peptide Therapy (nasal spray) — $159 a month on subscription for a one-month supply, or $199 one-time.
- NAD+ — $150 a month.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 5 products reviewed here. The evidence belongs to the molecule, not to Joi + Blokes.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Joi + Blokes’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Zepbound® (tirzepatide injection)Tirzepatide · FDA-approvedClaim matches the trials
“FDA-approved GLP-1/GIP medications for weight loss and type 2 diabetes, including Ozempic, Wegovy, Zepbound, and Mounjaro, may also be eligible for coverage.”
Read on the Joi + Blokes site, August 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Once-weekly tirzepatide versus placebo in adults with obesity or overweight, 72 weeks.
The branded products are described as what they are — FDA-approved, and identified as such in the same sentence that explains they may be insurance-eligible where the compounded products are not. On the approved side of the catalog the language is accurate throughout.1
Compounded GLP-1 / GLP-1+GIPSemaglutide · Compounded (503A)Claim reaches past the trials
“By utilizing the same bioidentical compound as Ozempic and Wegovy, Blokes can provide a cost-effective alternative. … At Blokes, we offer a cost-effective semaglutide option that is bioidentical with more expensive brands.”
Read on the Joi + Blokes site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Tested the approved semaglutide 2.4 mg product. No compounded semaglutide preparation, from any seller, has been through a registered trial.
FDA's position, in the June 2026 letter, is unambiguous: "Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." The word doing the damage is "bioidentical" — it is true about the molecule and it silently borrows the approval and the trial program that belong to the finished product.2
Sermorelin Peptide Therapy (injections or troches)Sermorelin · Compounded (503A)No trial supports this claim
“By month six, studies suggest potential 5-10% body fat reduction (without diet or exercise), a 10% increase in lean muscle mass, and improved overall vitality. … In the first month, many experience increased energy, improved stamina, and deeper sleep. By month two, improvements in skin, hair, nails, and metabolism may become noticeable.”
Read on the Joi + Blokes site, August 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None reports a body-fat percentage change, a lean-mass change, or any outcome at six months in healthy adults. A ClinicalTrials.gov search for sermorelin as an intervention returned 27 studies; the two closest to this marketed use, NCT01410799 and NCT00807365, are both phase 2 and both TERMINATED, at 13 and 5 participants.
Two numbers, a timeframe, and the words "studies suggest" — with no study named anywhere on the page. The parenthesis is the part to notice: "(without diet or exercise)" converts a hedged wellness claim into a specific promise about body composition achieved by the drug alone. Nothing in the sermorelin literature reports a 5-10% body-fat reduction or a 10% lean-mass gain at six months, because no trial has measured either.3
VIP Peptide Therapy (nasal spray)Vasoactive intestinal peptide (VIP) · Compounded (503A)No trial supports this claim
“Supports immune function. Reduces inflammation. Optimizes gut health. Supports joint health and mobility. Balances stress response. Supports cognitive function. … VIP is composed of 28 amino acid residues and is known to have numerous effects on development, growth, and the function of neuronal, epithelial, and endocrine cells.”
Read on the Joi + Blokes site, August 2026
No trial for this use
As of August 2026, ClinicalTrials.gov listed 19 studies with vasoactive intestinal peptide as an intervention. Reading the list, they fall into four groups: experimental headache induction in migraine research; pulmonary arterial hypertension (the pemziviptadil program, both trials TERMINATED); severe COVID-19 (the aviptadil program, including ACTIV-3b); and COPD. None studies immune function, inflammation, gut health, joint mobility, stress response or cognition in healthy adults, and none studies a nasal spray for wellness use.
The descriptive sentence about 28 amino acid residues is accurate textbook pharmacology and does no work. The six bullets above it are the claim, and "reduces inflammation" is stated flatly rather than hedged. The registered VIP literature is real and substantial — it is about pulmonary hypertension, COVID-19 and headache induction, at doses and by routes that have nothing to do with a wellness nasal spray. Having a serious literature about a different question is not the same as having evidence.4
NAD+Nicotinamide adenine dinucleotide (NAD+) · Compounded (503A)Claim reaches past the trials
“NAD+ — Supports cellular energy and metabolism. $150/mo”
Read on the Joi + Blokes site, August 2026
No trial for this use
As of August 2026, a PubMed search for "nicotinamide adenine dinucleotide" combined with intranasal and filtered to the randomized-controlled-trial publication type returned zero records. There is a genuine and growing randomized literature on oral NAD+ precursors such as nicotinamide riboside; it concerns different molecules given by a different route and does not transfer to an injected or intranasal NAD+ product.
"Supports cellular energy and metabolism" is a description of what NAD+ does inside a cell, which is uncontroversial biochemistry, presented as a reason to buy an injection. Whether administering NAD+ raises anything a person notices is the question, and it is the question the registered literature has not answered.5
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named anywhere on the sermorelin or VIP product pages. What the site does publish is the prescribing side, and publishes it clearly: "All prescriptions require a consultation with a licensed provider, either asynchronously or synchronously," and the three-step flow states that "[o]ur partner providers review your medical history and determine if a prescription is right for you." Partner providers, plural and unnamed. The insurance FAQ reveals a genuine split in the chain — estrogen, progesterone and thyroid medications "can be sent to your local pharmacy, where you may use your insurance benefits," while the compounded peptides cannot. So some prescriptions route to a pharmacy the patient chooses and some to one the company chooses, and only the first is identifiable. FDA's June 2026 letter makes the same point from the regulator's side: the compounded products "identify 'Joi + Blokes' on the pictured label, suggesting Joi + Blokes is the compounder of those drugs when in fact it is not."
Read on the Joi + Blokes site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No page reached in this review describes a testing regime for the compounded products — no potency specification, no sterility standard, no certificate of analysis, and no laboratory named. That is a notable absence for a company whose entire intake model is measurement: the storefront's most prominent products are diagnostic panels at $149, $399 and $699, and the pitch is "[d]ata-driven diagnostics and science-backed therapies." A customer is invited to measure 110 of their own biomarkers and given nothing measured about the drug. This is an absence claim about the pages searched on August 7, 2026 — the men's and women's sermorelin, VIP and NAD+ pages and the storefront navigation — not a claim that no such document exists anywhere.
Licensing
Licensed to dispense, and where
Coverage
Nationwide, with New York and New Jersey priced separately and an unnamed subset of products withheld by state
Read the full licensing claim
Joi + Blokes publishes no state licensure list. Two mechanisms in the storefront reveal that coverage is not uniform. A modal appears for New York and New Jersey visitors: "due to local state requirements, we have different pricing in these two states," and separately "due to local requirements we have different lab diagnostics pricing in these states." A second modal reads "Restricted Products Removed," which the cart shows when a product cannot be shipped to the address given. New York and New Jersey are listed as excluded here because they are the two states the site itself names; the honest position is that they are treated differently, not that they are unserved. Which products are withheld in which states is not published anywhere and can only be discovered by putting an address into a cart.
Named as outside that footprint
Read on the Joi + Blokes site, August 2026.
Regulatory
The FDA warning letter
Issued June 2026
Joi and Blokes dba Joi + Blokes — MARCS-CMS 728283. Concerns marketing and labeling.
Read the full allegation
FDA reviewed joiandblokes.com in March 2026 and cited two representations as false or misleading under FD&C Act sections 502(a) and 502(bb). First, that the compounded semaglutide and tirzepatide products pictured on the site "identify 'Joi + Blokes' on the pictured label, suggesting Joi + Blokes is the compounder of those drugs when in fact it is not." Second, two quoted claims — "By utilizing the same bioidentical compound as Ozempic and Wegovy, Blokes can provide a cost-effective alternative" and "At Blokes, we offer a cost-effective semaglutide option that is bioidentical with more expensive brands" — to which FDA responded: "Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." Both findings concern labeling and advertising. The letter makes no allegation about sterility, potency, contamination or any product-quality matter, and states that its list is not intended to be all-inclusive.
What has changed since
Partially re-checked on August 7, 2026. The word "bioidentical" does not appear on the men's sermorelin page, the men's VIP page or the storefront navigation. The compounded GLP-1 page at joiandblokes.com/glp-1/ returned a Cloudflare 403 to every request that day, so whether the quoted claims still appear there could not be established and is not asserted either way. FDA has published no close-out letter.
We did this ourselves
What happens when you sign up with Joi + Blokes
We went through Joi + Blokes’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Open a product page, where the subscription price and the one-time price sit side by side with the monthly equivalent worked out for you.
- Choose injections or troches.
- Press Get Started With Treatment, which drops a 12-week supply into the bag rather than starting any questions.
- A bag panel opens offering three subscription add-ons — an NAD+ nasal spray and two supplements.
- Press Checkout.
- Checkout is labeled 1 of 3: sign up, shipping address, payment.
- Give a first name, last name, email, phone number, date of birth and sex.
- Set a password for a new account. That is where this walk stopped.
- Every price is on the product page before anything is asked of you, and the page shows both the subscription rate and the undiscounted one-time rate. Most of this category shows neither.
- Not one health question is asked before the payment step. A prescription peptide goes into the bag and the next screen after that is the card.
- The category listing and the sermorelin product page quote different monthly figures for the same product. Re-checked 2026-08-25, both are still live and still disagree.
- The sermorelin subscription bills every three months, not monthly. Checkout names the next bill date, and the monthly number on the page is an equivalent rather than a charge.
- Both routes stop at the same gate. The checkout demands a password for a new account before it will show shipping, and the Schedule A Consult form opens a Please Set A Password modal at the end of the same fields.
- The bag pushes three add-on subscriptions between the product page and checkout, each with its own recurring charge.
- Joi + Blokes publishes a phone number and an email address on its contact page, but its live chat is behind a login.
- Rapamycin and low-dose naltrexone carry a Lab Required flag on the listing. Sermorelin does not, and no lab work was requested on the route walked here.
Joi + Blokes support
- Phone
- 720-828-8596
Assessment
What holds up, and what does not
- The intake is measurement-first, and the measurement is real: 56-, 71- and 110-biomarker panels at $149, $399 and $699, with an at-home draw option. Very little in this category asks for a blood test before writing a prescription.
- Prescriptions genuinely require a clinician. The site states that "[a]ll prescriptions require a consultation with a licensed provider, either asynchronously or synchronously," and rapamycin and enclomiphene carry a visible "Lab Required" flag.
- The subscription and one-time prices are published side by side on every product page, with the monthly equivalent computed for you — $559 per 12 weeks shown as $186.33 a month, $699 shown as $233. Almost nobody in this category shows the undiscounted price at all.
Show 3 more
- The branded GLP-1s are described accurately as FDA-approved and are distinguished from the compounded line in the insurance FAQ, which explains that only the approved products may be coverable.
- The company tells New York and New Jersey customers that their pricing differs by state before checkout rather than at it, and the cart names its own restriction when a product cannot ship.
- Some medications — estrogen, progesterone, thyroid — are routed to the customer's own local pharmacy so insurance can be used, which is a real concession of margin for the patient's benefit.
- "By month six, studies suggest potential 5-10% body fat reduction (without diet or exercise), a 10% increase in lean muscle mass." No study is named. None exists: the newest randomized trial in the sermorelin literature is from 2005 and measured growth hormone secretion.
- VIP is sold as a nasal spray that "[r]educes inflammation" and "[s]upports cognitive function." The 19 registered VIP trials concern pulmonary hypertension, severe COVID-19, COPD and experimental headache induction — none of them wellness use in healthy adults.
- Three prices exist for the same sermorelin product and only two of them are on the product page. The navigation advertises $199 a month; the page offers $186.33 or $233.
Show 4 more
- No testing disclosure of any kind for the compounded products — no potency tolerance, no sterility standard, no certificate of analysis, no laboratory named — on a site that sells 110-biomarker panels.
- No pharmacy is named. FDA's letter says the compounded labels carry the Joi + Blokes name while the company is not the compounder, and nothing published since identifies who is.
- There is no published state list. The only signal that a product cannot reach you is a "Restricted Products Removed" message once you have already put an address in a cart.
- Marketing leans on podcast association and on named longevity personalities — a customer testimonial on the VIP page invokes David Sinclair and Andrew Huberman by name. Neither has anything to do with the evidence for a VIP nasal spray.
Verdict
The bottom line
A number you can check is worth more than a hedge, and this one fails. Nothing in the sermorelin literature reports a 5-10% body-fat reduction or a 10% lean-mass gain at six months, because no trial measured either. Ask Joi + Blokes which studies the FAQ means — the intake and the lab work here are genuinely good, and that claim is not.
Opens joiandblokes.com. A link is not a recommendation to take anything.
The claim that can actually be checked
Almost all peptide marketing is written to be uncheckable. "May support." "Helps promote." "Part of a healthy lifestyle." You cannot falsify a hedge, which is the point of one.
Joi + Blokes does something different on its sermorelin page, and it deserves to be taken seriously for it. In the FAQ, under "What benefits should I expect to see (and when) from Sermorelin?", the answer walks month by month and lands here: "By month six, studies suggest potential 5-10% body fat reduction (without diet or exercise), a 10% increase in lean muscle mass, and improved overall vitality."
That is a real claim. It has two numbers, a timeframe, a stated mechanism of attribution — studies — and a parenthesis that removes the usual escape route by specifying that the change happens without diet or exercise. It can be checked. So it was.
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returns 19 records. The newest was published in 2005. 3 They are studies of growth hormone response to a challenge, of growth in children with growth hormone deficiency, of dose-response to a low-dose bolus, of what happens when you block the GHRH receptor. Not one of them reports a body-fat percentage. Not one reports a lean-mass change. Not one runs for six months in healthy adults, because that is not the question anyone was asking.
ClinicalTrials.gov gives the same answer from the registry side. Twenty-seven studies list sermorelin as an intervention. The two that come closest to the marketed use — NCT01410799, three months of GHRH in the elderly, and NCT00807365, the six-month version — are both phase 2 and both TERMINATED, having enrolled 13 and 5 participants respectively.
So the honest description of "studies suggest potential 5-10% body fat reduction" is that no study suggests it, because no study has looked. This site's editorial policy has a line about exactly this construction: "'Studies suggest', 'research shows', and 'experts agree' are not evidence — they are ways of avoiding a citation." What is unusual here is that the avoidance comes with a number attached, which makes it worse and easier to check at the same time.
None of this means sermorelin does nothing, and this review does not say it is unsafe. It is a growth-hormone-releasing hormone analog and it does stimulate pituitary GH release — that mechanism is well established, and it is why the drug existed as a diagnostic agent. The gap is between a mechanism and an outcome, and it is the whole gap.
Full analysis — 5 more sectionsVIP, and a literature about a different question · What the FDA letter says, and what it does not · The measurement paradox · The three prices · What to take from this
VIP, and a literature about a different question
The second peptide is stranger, because the evidence base is substantial and points somewhere else entirely.
The product is vasoactive intestinal peptide as a nasal spray, $159 a month on subscription. The page's bullets: "Supports immune function. Reduces inflammation. Optimizes gut health. Supports joint health and mobility. Balances stress response. Supports cognitive function." Above them, a paragraph that is straightforwardly correct — VIP "is composed of 28 amino acid residues and is known to have numerous effects on development, growth, and the function of neuronal, epithelial, and endocrine cells."
That paragraph is textbook pharmacology and it is doing rhetorical work rather than evidential work. The bullets are the claim, and "reduces inflammation" is stated flatly, without the hedging every other line carries.
As of August 2026, ClinicalTrials.gov lists 19 studies with vasoactive intestinal peptide as an intervention. 4 They sort into four groups and none is about wellness. There is a headache-research group, where VIP is infused into volunteers deliberately to induce migraine and study the mechanism. There is a pulmonary arterial hypertension group built around pemziviptadil, a long-acting VIP analog, whose phase 2 trials were both terminated. There is a severe-COVID group built around aviptadil, including the phase 3 ACTIV-3b program. And there is a small COPD group.
Serious science, real trials, substantial enrollments — and all of it concerns intravenous or inhaled administration in acutely ill patients for cardiopulmonary indications. Not one study concerns immunity, gut health, joint mobility, stress or cognition in a healthy adult, and none concerns a wellness nasal spray. Having a real literature about a different question is not the same as having evidence, and a reader who searches "VIP clinical trials" will find plenty of hits and draw exactly the wrong conclusion.
The page's social proof completes the picture. A customer testimonial reads: "Peptides have a really big anti-aging community. You may have heard of it from David Sinclair or Andrew Huberman. Some of the benefits I noticed right away are increased recovery, better mood, and more energy." Two names, neither of whom has published anything about a VIP nasal spray, standing in for the citation that is not there.
What the FDA letter says, and what it does not
On June 8, 2026, FDA wrote to Joi and Blokes after reviewing joiandblokes.com in March. Two allegations, both misbranding under sections 502(a) and 502(bb), both about advertising and labeling. 6
The first is now a familiar pattern across this enforcement wave: the compounded semaglutide and tirzepatide products pictured on the site "identify 'Joi + Blokes' on the pictured label, suggesting Joi + Blokes is the compounder of those drugs when in fact it is not."
The second is the substantive one, and FDA quotes the site directly: "By utilizing the same bioidentical compound as Ozempic and Wegovy, Blokes can provide a cost-effective alternative," and "At Blokes, we offer a cost-effective semaglutide option that is bioidentical with more expensive brands." FDA's answer is three sentences and worth reading slowly: "Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not."
The mechanism is the word "bioidentical." It is true at the level of the molecule, and it quietly transfers the approval and the entire trial program that belong to the finished product — 1,961 participants in STEP 1 for semaglutide 2, 2,539 in SURMOUNT-1 for tirzepatide 1 — onto a preparation that has never been in a trial. Nothing false is stated. The inference does all the work.
What the letter does not contain matters just as much. There is no allegation about sterility, potency, contamination or any other aspect of product quality. A warning letter is a public regulatory communication, not a finding of illegal activity, not an injunction and not a shutdown; firms across this wave have responded with corrective action and continued trading. It is disclosed here because a reader deciding where to spend $186 a month should know it exists, and it is not treated as disqualifying because it is not.
On the follow-up check: the word "bioidentical" does not appear on the men's sermorelin page, the men's VIP page or the storefront navigation as they stood on August 7, 2026. The compounded GLP-1 page itself returned a Cloudflare 403 to every request that day, so whether the quoted sentences survive there is unknown and this review does not guess.
The measurement paradox
Here is the thing that makes Joi + Blokes genuinely interesting rather than simply another peptide storefront.
The company's whole proposition is measurement. Its most prominent products are diagnostic panels: the Complete Hormone Panel at $149 covering 56 biomarkers, the Advanced Panel at $399 covering 71, the Comprehensive Panel at $699 covering 110. Rapamycin and enclomiphene carry a visible "Lab Required" flag. The homepage promise is "[d]ata-driven diagnostics and science-backed therapies." Prescriptions require a clinician, stated plainly: "All prescriptions require a consultation with a licensed provider, either asynchronously or synchronously."
That is a better intake than most of this market offers, and it is not marketing dressing — asking for 110 biomarkers before prescribing is a real cost the company chose to bear.
And then nothing is measured about the drug. Across the men's and women's sermorelin, VIP and NAD+ pages and the storefront navigation, searched on August 7, 2026, there is no potency tolerance, no sterility standard, no certificate of analysis, no laboratory named, and no pharmacy named. For comparison, the compounded-peptide seller reviewed alongside this one at least publishes its testing cadence — enough detail to reveal that its potency test runs every three to six months rather than per batch. Joi + Blokes publishes neither the cadence nor the standard.
So a customer is invited to quantify 110 things about their own body and given zero quantified facts about the vial. Whatever the panels are measuring, it is not the variable most likely to determine whether the treatment does anything.
The three prices
A smaller point, but the kind that tells you how carefully a page was assembled.
The site navigation lists, under Popular Products, "Sermorelin Peptide Therapy — Peptide associated with growth hormone signaling. $199/mo." The sermorelin product page offers exactly two ways to buy: $559 for a 12-week supply on subscription, which the page renders as $186.33 a month, or $699 one-time, rendered as $233 a month.
$199 is neither. It is not the subscription rate, it is not the one-time rate, and it is not an average of them. It appears on every page of the site as the price of the product, in the same navigation panel that correctly lists NAD+ at $150 and VIP at $159.
None of these figures is hidden and the product page is admirably explicit — showing the undiscounted price next to the subscription price is more than most competitors do. But a reader who decides to buy at the advertised $199 will be charged something else, in one direction or the other, depending on which option they pick.
What to take from this
The split in this company runs cleanly along one line: everything about the process is better than the category average, and everything about the claims is worse.
If you are here for the approved GLP-1s, the descriptions are accurate, the branded products are distinguished from the compounded ones, and you will be told which may be insurance-eligible. That is a competent service.
If you are here for the peptides, understand what you are buying. Sermorelin's mechanism is real and its outcomes are unstudied; the specific numbers on the page come from nowhere. VIP has a serious clinical literature about pulmonary hypertension and severe COVID-19 and none at all about the six things the bullets promise. NAD+ by injection has no randomized evidence, whatever the oral-precursor literature shows.
None of that means these molecules do nothing, and this site does not tell anyone what to take — the reconstitution tools here convert numbers and never suggest a dose, and what to do about any of this is a conversation with a clinician. It means the evidence is not what the page implies, and the page implies it with a precision that ought to be reserved for facts.
Questions
Frequently asked questions
Do studies really show 5-10% body fat reduction from sermorelin?
No study reports that. The claim appears in Joi + Blokes' own sermorelin FAQ — "[b]y month six, studies suggest potential 5-10% body fat reduction (without diet or exercise), a 10% increase in lean muscle mass" — and no study is named. As of August 2026, a PubMed search for sermorelin filtered to randomized controlled trials returns 19 records, the newest from 2005, and every one measures growth hormone secretion, growth in children, or a diagnostic response. None reports body fat or lean mass. On ClinicalTrials.gov, 27 sermorelin studies are registered; the two closest to this use are phase 2 and were terminated at 13 and 5 participants. Sermorelin does stimulate growth hormone release — that mechanism is well established. The outcomes on the page have not been measured.
What is VIP and is there evidence for it?
Vasoactive intestinal peptide is a real 28-amino-acid signaling peptide, and there is real clinical research on it — about the wrong things for this product. As of August 2026, ClinicalTrials.gov lists 19 studies with VIP as an intervention: experimental headache induction in migraine research, pulmonary arterial hypertension (the pemziviptadil trials, both terminated), severe COVID-19 (the aviptadil program including phase 3 ACTIV-3b), and COPD. None studies immune function, inflammation, gut health, joint mobility, stress or cognition in healthy adults, and none studies a nasal spray for wellness. A search that returns 19 trials looks like evidence until you read what they are.
What did the FDA warning letter to Joi + Blokes say?
It was issued June 8, 2026 (MARCS-CMS 728283) after FDA reviewed joiandblokes.com in March 2026. Two allegations, both misbranding under FD&C Act 502(a) and 502(bb). One: the pictured compounded labels carry the Joi + Blokes name, "suggesting Joi + Blokes is the compounder of those drugs when in fact it is not." Two: the site claimed its compounded semaglutide used "the same bioidentical compound as Ozempic and Wegovy" and was "bioidentical with more expensive brands," to which FDA replied that "[c]ompounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." There is no allegation about sterility, potency or contamination. A warning letter is a public regulatory communication, not a finding of illegal activity, and does not stop a company operating.
Has Joi + Blokes changed the language FDA objected to?
Partly, as far as could be checked. On August 7, 2026 the word "bioidentical" did not appear on the men's sermorelin page, the men's VIP page or the storefront navigation. The compounded GLP-1 page at joiandblokes.com/glp-1/ returned a Cloudflare 403 to every request that day, so whether the two quoted sentences still appear there could not be established, and this review does not assert either way. FDA has published no close-out letter.
Who compounds the peptides, and are they tested?
Neither question is answered on the site. No pharmacy is named on any product page reached in this review — the closest statement is that "[o]ur partner providers review your medical history," which describes the prescribers rather than the compounder. FDA's letter states directly that Joi + Blokes is not the compounder despite its name being on the pictured labels. On testing, nothing: no potency tolerance, no sterility standard, no certificate of analysis and no laboratory named across the men's and women's sermorelin, VIP and NAD+ pages or the navigation, searched August 7, 2026. That is an unusual gap for a company whose headline products are 56-, 71- and 110-biomarker diagnostic panels.
What does sermorelin actually cost here?
The product page publishes two options: $559 for a 12-week supply on subscription, which the page itself renders as $186.33 a month, or $699 one-time, rendered as $233 a month. The site navigation separately advertises "Sermorelin Peptide Therapy … $199/mo," which matches neither. All three figures were read on August 7, 2026. Injections and troches are offered as alternative delivery methods at the same listed price. Joi + Blokes does not bill insurance directly.
Does Joi + Blokes ship to my state?
There is no published state list, which is the honest answer and an unsatisfying one. Two things are visible from outside. Visitors in New York and New Jersey get a modal saying that "due to local state requirements, we have different pricing in these two states," applying separately to treatments and to lab diagnostics. And the cart can display "Restricted Products Removed," meaning at least some products are withheld by shipping address. Which products, in which states, is not published and can only be discovered by entering an address at checkout.
Is the lab testing worth it?
The panels are real, and requiring a blood draw before prescribing is better practice than most of this category. A 56-biomarker hormone panel at $149, 71 at $399 and 110 at $699, with an at-home draw option, is a genuine service and a genuine cost the company chose to bear. What a panel cannot do is establish that a peptide with no outcome trials will change any of the numbers it measures. Measuring your baseline carefully and then treating it with something unstudied leaves you with a precise before and an uninterpretable after. This site does not advise for or against any test or treatment — that is a conversation with a clinician.
Glossary
Key terms
Show definitions
- Bioidentical
- Chemically identical to a reference molecule. It says nothing about whether the finished preparation has been approved, tested, or made to a known strength — which is why FDA cited its use here as implying an approval that does not exist.
- Vasoactive intestinal peptide (VIP)
- A 28-amino-acid signaling peptide with effects on neuronal, epithelial and endocrine cells. Its registered clinical trials concern pulmonary hypertension, severe COVID-19, COPD and experimental headache induction — not wellness use in healthy adults.
- Troche
- A lozenge dissolved in the mouth so the drug is absorbed through the lining rather than swallowed. Offered here as an alternative to injection; the two routes are not automatically equivalent and neither has been tested for these outcomes.
- Asynchronous consultation
- A clinician reviews a written intake and decides without a live conversation. Legal in most states and used widely in telehealth; it is a lower-touch encounter than a synchronous visit, and the site discloses that it uses both.
- "Studies suggest"
- A construction that attributes a claim to a literature without naming any part of it. On this site it is treated as the absence of a citation rather than the presence of evidence — see the editorial policy.
Compare
Others selling what Joi + Blokes sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Joi + Blokes's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 6 sources
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; and ClinicalTrials.gov search: intervention "sermorelin" — 27 studies. Both run 2026-08-07. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). ClinicalTrials.gov search: intervention "vasoactive intestinal peptide" — 19 studies, spanning migraine induction, pulmonary arterial hypertension, severe COVID-19 and COPD. Run 2026-08-07. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/search?intr=vasoactive%20intestinal%20peptide
- US National Library of Medicine (2026). PubMed search: "nicotinamide adenine dinucleotide" AND intranasal AND randomized controlled trial[pt] — 0 records. Run 2026-08-07. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=%22nicotinamide+adenine+dinucleotide%22+AND+intranasal+AND+randomized+controlled+trial%5Bpt%5D
- US Food and Drug Administration, Center for Drug Evaluation and Research (2026). Warning Letter to Joi and Blokes dba Joi + Blokes, MARCS-CMS 728283. fda.gov. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/joi-and-blokes-dba-joi-blokes-728283-06082026
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.